Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer To Close New London facility
Pfizer has announced that as apart of global research facility strategy under Wyeth merger, will close six sites including New London facility. The staff froms New London facility
Pfizer has announced that as apart of global research facility strategy under Wyeth merger, will close six sites including New London facility. The staff froms New London facility
The researchers of Riken and Yokohama City University have reported that a key mechanism involved in immune surveillance in the intestinal system. Their research is expected to appear
Abbott has entered into an agreement to acquire the global rights to PanGenetics’ PG110, a fully humanised antibody to Nerve Growth Factor (NGF). The move would expand the
Cequent Pharmaceuticals (Cequent) has filed an investigational new drug (IND) application with the FDA. CEQ508, an orally administered tkRNAi drug candidate, targets beta-catenin, a key oncogene implicated in
Ionian Technologies and Roche Diagnostics have entered into a molecular diagnostic manufacturing agreement based on Ionian’s rapid isothermal nucleic acid amplification technology. Under this collaboration, Roche is expected
Lexicon Pharmaceuticals has reported that the company’s investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating
Bioniche Pharma has reported the acquisition of Duraclon (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals. The company said that Duraclon (clonidine hydrochloride injection) has
AkzoNobel is to enhance its portfolio of sustainable technologies after signing an agreement with the Dow Chemical Company (Dow) to acquire its powder coatings activities. Financial details were
Shire has reported findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity
The Medicines Company reported interim data from the evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment (ACCELERATE) trial. The study was presented at